Claims for Patent: 5,736,323

Summary for Patent: 5,736,323

Title:	Agents and procedures for the study of the genetic polymorphism of the angiotensin I converting enzyme
Abstract:	The invention discloses a method for detecting polymorphism in the angiotensin converting enzyme by means of a chain amplification technique, the aim being to detect whether or not the sequence of nucleotides 1451-1738 of intron 16 is present in the human angiotensin converting enzyme gene.
Inventor(s):	Soubrier; Florent (Paris, FR), Hubert; Christine (Sevres, FR), Corvol; Pierre (Paris, FR)
Assignee:	Institut National de la Sante et de la Recherche Medicale (Paris, FR)
Application Number:	08/157,171
Patent Claims:	1. A DNA fragment consisting of at least about 8 to about 1856 consecutive nucleotides of a sequence of intron 16 (SEQ. ID NO:3) of a human angiotensin converting enzyme gene. 2. The DNA fragment according to claim 1, wherein the fragment consists of all or part of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:8) of a human angiotensin converting enzyme gene. 3. The DNA fragment according to claim 2, wherein the sequence of the fragment consists of a subsequence of SEQ. ID NO:8. 4. A DNA fragment wherein the fragment consists of at least 8 contiguous nucleotides from nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) of a human angiotensin converting enzyme gene and at least one of the sequences flanking nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) of a human angiotensin converting enzyme gene, wherein the flanking sequences consist of sequences from intron 16, exon 16, or exon 17 of a human angiotensin converting enzyme gene. 5. The DNA fragment according to claim 1, wherein the sequence in the DNA of intron 16 includes nucleotides 1-1450 or 1739-1856 of intron 16 (SEQ ID NO:3) of a human angiotensin converting enzyme gene. 6. The DNA fragment according to claim 1, wherein the fragment consists of about 15 to about 40 nucleotides. 7. A pair of DNA fragments according to claim 1, wherein the fragments are primers used in a sequence amplification. 8. The primers according to claim 7, wherein the sequence is amplified using a polymerase chain reaction. 9. The primers according to claim 7, wherein the pair of DNA fragments comprise a first primer and a second primer, which primer pair is selected from the group consisting of: a primer pair in which the first primer consists of a subsequence of nucleotides 1-1450 of intron 16 (SEQ. ID NO:3); and a primer pair in which the first primer consists of a subsequence of nucleotides 1-1737 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1739-1856 of intron 16 (SEQ. ID NO:3). 10. The primers according to claim 7, wherein the pair of DNA fragments comprise a first primer and a second primer, which primer pair is selected from the group consisting of: a primer pair in which the first primer is a subsequence of intron 16 and comprise nucleotide 1451 of intron 16 (SEQ. ID NO:3) and the second primer is a subsequence of intron 16 and comprises nucleotide 1738 of intron 16 (SEQ. ID NO:3); and a primer pair in which the sequence of the first primer and the sequence of the second primer each consist of from 15 to 40 consecutive nucleotides outside of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3). 11. The primers according to claim 7, wherein the pair of DNA fragments comprise a first primer and a second primer which primer pair is selected from the group consisting of: a primer pair in which the first primer is a subsequence of intron 16 and comprises nucleotide 1451 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3); a primer pair in which the first primer is a subsequence of intron 16 and comprises nucleotide 1738 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3); and a primer pair in which the first primer consists of a sequence of from 15 to 40 nucleotides that lies outside of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) and the second primer consists of a of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3). 12. A pair of DNA fragments used as primers for amplifying a sequence of intron 16 (SEQ. ID NO:3) of a human angiotensin converting enzyme gene. 13. The pair of DNA fragments used as primers according to claim 12, wherein a first primer consists a sequence selected from the group consisting of a subsequence of intron 15 (SEQ. ID NO:1), a subsequence of exon 16 (SEQ. ID NO:2), a subsequence of exon 17 (SEQ. ID NO:4), a subsequence of intron 17 (SEQ. ID NO:5), a subsequence of exon 18 (SEQ. ID NO:6), and a subsequence of intron 18 (SEQ. ID NO:7) and a second primer consists of a different sequence from said first primer and is selected from the group consisting of a subsequence of intron 15 (SEQ. ID NO:1), a subsequence of exon 16 (SEQ. ID NO:2), a subsequence of exon 17 (SEQ. ID NO:4), a subsequence of intron 17 (SEQ. ID NO:5), a subsequence of exon 18 (SEQ. ID NO:6), and a subsequence of intron 18 (SEQ. ID NO:7). 14. The pair of DNA fragments used as primers according to claim 12, wherein the pair of DNA fragments comprise a first primer and a second primer, wherein the first primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) and the second primer comprises a sequence selected from the group consisting of a subsequence of intron 15 (SEQ. ID NO:1), a subsequence of exon 16 (SEQ. ID NO:2), a subsequence of exon 17 (SEQ. ID NO:4), a subsequence of intron 17 (SEQ. ID NO:5), a subsequence of exon 18 (SEQ. ID NO:6), and a subsequence of intron 18 (SEQ. ID NO:7). 15. A pair of DNA fragments according to claim 12, wherein the sequence is amplified using a polymerase chain reaction. 16. A method for the detection of a polymorphism within a gene for angiotensin converting enzyme in a biological sample, the method comprising the steps of: hybridizing a pair of primers to a DNA sequence encoding a human angiotensin converting enzyme; amplifying said DNA sequence; and detecting the presence or absence of all or part of nucleotides 1451-1738 (SEQ. ID NO:8) of intron 16 (SEQ. ID NO:3) of the human angiotensin converting enzyme gene. 17. The method according to claim 16, wherein the sequence is amplified using a polymerase chain reaction. 18. The method according to claim 16, wherein said sequence amplification step includes a pair of primers. 19. The method according to claim 18, wherein each primer of the pair of primers consists of at least about 8 to about 1856 consecutive nucleotides of a sequence in intron 16 (SEQ. ID NO:3) of a human angiotensin converting enzyme gene. 20. The method according to claim 19, wherein the pair of primers comprises a first primer and a second primer, which primer pair is selected from the group consisting of: a primer pair in which the first primer consists of a subsequence of nucleotides 1-1450 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1452-1856 of intron 16 (SEQ. ID NO:3); and a primer pair in which he first primer consists of a subsequence of nucleotides 1-1737 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1739-1856 of intron 16 (SEQ. ID NO:3). 21. The method according to claim 19, wherein sequence amplification comprises a first primer and a second primer, which primer pair is selected from the group consisting of: a primer pair in which the first primer is a subsequence of intron 16 and comprises nucleotide 1451 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of intron 16 and comprises nucleotide 1738 of intron 16 (SEQ. ID NO:3); a primer pair in which the first primer is a subsequence of intron 16 and comprises nucleotide 1738 of intron 16 (SEQ. ID NO:3) and the second primer is subsquence of intron 16 an comprises nucleotide 1451 of intron 16 (SEQ. ID NO:3); and a primer pair in which the sequence of the first primer and the sequence of the second primer each consist of sequences that lie outside of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3). 22. The method according to claim 19, wherein the pair of primers comprises a first primer and a second primer, which primer pair is selected from the group consisting of: a primer pair in which the first primer is subsequence of intron 16 and comprises nucleotide 1451 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3); and a primer pair in which the first primer is a subsequence of intron 16 and comprises nucleotide 1738 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3); and a primer pair in which the first primer consists of a sequence that lies outside the range of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) and the second primer consists of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3). 23. The method according to claim 18, wherein each of the pair of primers has a sequence selected from the group consisting of a subsequence of intron 15 (SEQ ID NO:1), a subsequence of exon 16 (SEQ ID NO:2), a subsequence of exon 17 (SEQ ID NO:4), a subsequence of intron 17 (SEQ ID NO:5), a subsequence of exon 18 (SEQ ID NO:6), and a subsequence of intron 18 (SEQ ID NO:7). 24. The method according to claim 18, wherein the pair of primers includes a first primer and a second primer, the first primer consisting of a subsequence of nucleotides 1451-1738 of intron 16 (SEQ. ID NO:3) and the second primer consists of a sequence selected from the group consisting of a subsequence of intron 15 (SEQ. ID NO:1), a subsequence of exon 16 (SEQ. ID NO:2), a subsequence of exon 17 (SEQ. ID NO:4); a subsequence of intron 17 (SEQ. ID NO:5), a subsequence of exon 18 (SEQ. ID NO:6), and a subsequence of intron 18 (SEQ. ID NO:7). 25. A DNA fragment comprising at least about 8 to 1856 consecutive nucleotides of a sequence of intron 16 SEQ. ID NO:3) of a human angiotensin converting enzyme gene.

Details for Patent 5,736,323

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-04-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-04-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-04-07